Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Trials is Scopus-indexed (Q2, CiteScore 3.9), WoS SCIE, DOAJ. Published by BioMed Central Ltd.
Checked against the index lists dated .
ISSN 1745-6215Verify ISSN ↗
Publisher: BioMed Central Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medicine (miscellaneous) | 161 / 466 | 65th | Q2 |
| Pharmacology (medical) | 138 / 278 | 50th | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q2, CiteScore 3.9.
Trials is Q2 in Medicine (miscellaneous) (rank 161 of 466) and Q2 in Pharmacology (medical) (rank 138 of 278), by CiteScore 2025.
Trials is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.9, which places it in quartile Q2 at the 65th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.892, quartile Q2, with an H-index of 111.
The publisher lists an article processing charge of about US$2,790 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Trials is published by BioMed Central Ltd. Its ISSN is 1745-6215.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Trials has an h-index of 133 and a 2-year mean of 2.36 citations per paper (OpenAlex). Its Scopus CiteScore is 3.9, quartile Q2. On 2-year citations it ranks #143 of 451 Scopus journals in Medicine (miscellaneous).
Trials published 680 papers in 2025; its busiest recent year was 2022 with 1,080. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2026), authors are most often from China (20.9%), United Kingdom (17.5%) and United States (11%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 8 retracted papers are recorded (0.6 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.